Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

Open, Booster Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Administered to Healthy Chinese Children 6-8 Years of Age.

This study will evaluate the safety and reactogenicity of booster dose of GSK Biologicals' dTpa vaccine (Boostrix) in Chinese children at 6-8 years of age.

Inclusion Criteria:

• A male or female between, and including, 6-8 years of age at the time of vaccination,
• Written informed consent obtained from the parent or guardian of the subject,
• Subjects who have received a total of 4 doses of DTP vaccine in the first 2 years of life,

Exclusion Criteria:

• subjects who have received previous DTP booster vaccination since administration of the fourth dose of vaccine in second year of life can not participate
• Subjects with history of diphtheria, pertussis or tetanus diseases can not participate